Acute-phase proteins in osteoarthritis
- PMID: 8578314
- DOI: 10.1016/s0049-0172(95)80020-4
Acute-phase proteins in osteoarthritis
Abstract
The joint destruction of osteoarthritis (OA) comprises loss of articular cartilage resulting from an imbalance of enzyme-catalized cartilage breakdown and regeneration. OA is thought to derive from defective chondrocyte metabolism and thus to inherently lack the large-scale systemic response that is the hallmark of rheumatoid arthritis (RA). Because of the apparent absence of systemic inflammation in OA, acute-phase response proteins have not been as extensively studied in OA as they have been in RA. The diagnosis of OA almost always involves radiographic assessment of joint damage, which is useful only after the disease process has been underway for several months. Radiographic evaluation cannot give a good assessment of current disease activity and is a relatively insensitive indicator of prognosis. Cartilage breakdown products can potentially serve as direct surrogate markers of OA disease activity, but have not been extensively used because of their limited sensitivity and the technical difficulties associated with their measurement. Markers of disease activity in RA are indirect and are derived from the acute-phase response, a cycle of temporal changes in cellular and metabolic function. The early part of the acute-phase response involves the local action and production of cytokines such as interleukin-1 (IL-1), tumor necrosis factor (TNF-alpha) and IL-6. In the late acute-phase response, these cytokines can effect many systemic changes, including increased production of acute-phase proteins (APP). Three valuable surrogate markers of disease activity in RA are provided by the acute-phase response: the time-honored erythrocyte sedimentation rate (ESR) and the newer APPs C-reactive protein (CRP) and serum amyloid A (SAA). As in RA, the joint destruction of OA involves IL-1, TNF-alpha, and IL-6; however, OA can be viewed as an indolent stimulus of the later (systemic) acute-phase response. Recent studies of the acute-phase response in OA suggest that the concentrations of CRP and SAA are elevated in OA, but to a lesser extent than in RA. In the future, long-term monitoring of CRP concentrations in the blood may permit the earlier detection and more effective treatment of OA.
Similar articles
-
Ferritin correlates with C-reactive protein and acute phase serum amyloid A in synovial fluid, but not in serum.Amyloid. 1999 Jun;6(2):130-5. doi: 10.3109/13506129909007314. Amyloid. 1999. PMID: 10439120
-
Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis.Mol Med Rep. 2015 Feb;11(2):1528-34. doi: 10.3892/mmr.2014.2804. Epub 2014 Oct 29. Mol Med Rep. 2015. PMID: 25352049
-
The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors.Arthritis Res Ther. 2011 Mar 24;13(2):R50. doi: 10.1186/ar3293. Arthritis Res Ther. 2011. PMID: 21435227 Free PMC article.
-
The role of cytokines in osteoarthritis pathophysiology.Biorheology. 2002;39(1-2):237-46. Biorheology. 2002. PMID: 12082286 Review.
-
Acute phase proteins in the monitoring of inflammatory disorders.Baillieres Clin Rheumatol. 1994 Aug;8(3):531-52. doi: 10.1016/s0950-3579(05)80114-1. Baillieres Clin Rheumatol. 1994. PMID: 7525084 Review.
Cited by
-
Is the prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with disease?Rheumatol Int. 2013 May;33(5):1185-92. doi: 10.1007/s00296-012-2522-1. Epub 2012 Sep 11. Rheumatol Int. 2013. PMID: 22965673
-
The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis.BMC Vet Res. 2013 Mar 1;9:42. doi: 10.1186/1746-6148-9-42. BMC Vet Res. 2013. PMID: 23452411 Free PMC article.
-
High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life.Arthritis Res Ther. 2008;10(1):R27. doi: 10.1186/ar2380. Epub 2008 Feb 29. Arthritis Res Ther. 2008. PMID: 18312679 Free PMC article.
-
Efficacy and safety of low-dose rosuvastatin/ezetimibe for dyslipidemia in patients with rheumatoid arthritis or osteoarthritis.Medicine (Baltimore). 2025 Jul 4;104(27):e43133. doi: 10.1097/MD.0000000000043133. Medicine (Baltimore). 2025. PMID: 40631878 Free PMC article. Clinical Trial.
-
Synovial fluid proteome profile of surgical versus chemical induced osteoarthritis in rabbits.PeerJ. 2022 Feb 23;10:e12897. doi: 10.7717/peerj.12897. eCollection 2022. PeerJ. 2022. PMID: 35228907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous